Which act encouraged manufacturers to research new uses for drugs and submit Supplemental New Drug Applications (SNDAs)?

The FDA Modernization Act of 1997 significantly encouraged manufacturers to explore new applications for existing drugs. This act streamlined the regulatory process, allowing for more efficient review of Supplemental New Drug Applications (SNDAs). By reducing barriers and increasing incentives for pharmaceutical companies to conduct research into additional therapeutic uses of their drugs, the act aimed to promote innovation within the industry.

Within the context of FDA history, the act also updated various provisions related to drug approval, ensuring that companies could more readily submit applications for new indications or formulations without facing excessive delays. This focus on encouraging manufacturers to research and submit SNDAs was central to the act's goals of enhancing public health by making new therapies available more quickly.

The other acts mentioned, while impactful, primarily addressed different aspects of drug regulation, such as safety and efficacy requirements, or the need for prescription labeling. They do not specifically target manufacturers' encouragement to research new applications as the FDA Modernization Act does.